title: Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation.
abstract: The antitumor effects of two iridoid compounds, geniposidic acid (GA) and geniposide (GP), were investigated in mice along with their possible effects on radioprotection after sublethal X-irradiation. Decreases in the growth of the implanted tumor by ascitic cells were a result of intraperitoneal administration of GA and GP at high concentrated levels. This result was achieved by exerting the levels of dosage in a dose-dependent manner. Except on the 12th day after treatment by the dosage of 500 mg/kg, reduced radiation effects of mice treated with the drugs in the 30 min preirradiated period by GA and GP on peripheral leukocytes were not observed significantly by the sublethal whole-body X-irradiation. And except on the 7th day after treatment, when these two compounds were administered i.p. to mice 30 min before 4 Gy irradiation, neither GA nor GP enhanced significantly the postirradiation responses of splenic blastogenesis by PHA. In addition, GA might be a more potent tumor growth inhibitor than GP when combined with the X-irradiation, though there was no significant synergetic effect on their combined antitumor activity. The preliminary results of GA and GP on hematological and blastogenic observations in this study suggested that they may very well, partially, play a role in an effective anticancer product with the ability to decrease undesirable radiation damage to the hematologic tissue after high dose irradiation.
authors.affiliation: Department of Radiotherapy, Kaohsiung Medical College, Taiwan, ROC.
authors.forename: H Y
authors.initials: HY
authors.lastname: Hsu
authors.forename: J J
authors.initials: JJ
authors.lastname: Yang
authors.forename: S Y
authors.initials: SY
authors.lastname: Lin
authors.forename: C C
authors.initials: CC
authors.lastname: Lin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005960:Glucosides / Q000627:therapeutic use*; D057888:Iridoid Glucosides; D039823:Iridoids; D007958:Leukocyte Count / Q000187:drug effects / Q000528:radiation effects; D008213:Lymphocyte Activation / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011714:Pyrans / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D013997:Time Factors; D014916:Whole-Body Irradiation
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D005960:Glucosides; D057888:Iridoid Glucosides; D039823:Iridoids; D011714:Pyrans; D011837:Radiation-Protective Agents; C007835:geniposide; C058966:geniposidic acid